Rheumnow Podcast Dr. Cush

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Giant Cell Arteritis and Polymyalgia Rheumatica UpdateDr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New IndicationsDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Pain in RA: Different Drugs for Different MechanismsDr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Top 3 Messages About JAK Inhibitor SafetyDr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
DMARDs and Herpes Zoster Vaccination: To Stop or Not To StopDr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Has JAK POT Hit the Spot About Infection Risk?Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Select your GCA TherapyDr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
 

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.
OP0046 Effect on SI joint structural lesions with ixekizumabPOS0058 Effect on SI joint structural lesions with bimekizumab
Does Telemonitoring in SpA Work?Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria.
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpADr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
Treat to Target Outcomes in Early AxSpADr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.
Early Diagnosis of Axial SpondyloarthritisDr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.
Imaging in Axial SpondyloarthritisDr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.

Does B Cell Depletion Matter?Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
3 Big Lupus Themes from EULAR 2024Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria. POS0732OP0255
Voclosporin and Steroids in Lupus NephritisDr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
JAK Inhibitors for New IndicationsDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
Cognitive Function in Older Adults with LupusDr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
Does Withdrawing Steroids Increase Flares in SLE?Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria.
Tapering Treatment for LupusDr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.
The Crossroads of Autoinflammation and AutoimmunityDr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria.
We've Got to Talk about CAR T cellsDr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.
 
 

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
JAK Inhibitors for New IndicationsDr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
PsA Treatment: is Earlier Better?Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
Transition from Psoriasis to PsA: Can we Prevent It?Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsADr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
PsA Switch or Cycle, the Eternal QuestionDr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
Axial & Psoriatic DiseaseDr. Peter Nash at Eular 2024 in Vienna, Austria.
Difficult to Treat Psoriatic ArthritisDr. Peter Nash reports at Eular 2024 in Vienna, Austria.
Predictors of Treatment Response in Psoriatic ArthritisDr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed: POS 0990POS 0992POS 0266
Prevention of Psoriatic ArthritisDr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
 

Mechanistic Promise in RA Doesn’t Always Mean Actual GainDr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
The Role of Psychosocial Determinants in the Management of Rheumatoid ArthritisDr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
A Step Closer to Identifying Phenotypes of RA ILDDr. Mrinalini Dey discusses abstract OP0202 presented at Eular 2024 in Vienna, Austria.
Pain in RA: Different Drugs for Different MechanismsDr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086.
Predicting Palindromic PrognosisDr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
Top 3 Messages About JAK Inhibitor SafetyDr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Abatacept Misses on Shingrix ResponseDr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
Artificial Intelligence Detection of CPPD on Hand RadiographsDr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria.
Cognitive Function in Older Adults with LupusDr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
Difficult-to-treat Rheumatoid Arthritis Validation of the EULAR DefinitionDr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
DMARDs and Herpes Zoster Vaccination To Stop or Not To StopDr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
Has JAK POT Hit the Spot About Infection Risk?Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
Inspirations About RA-ILDDr. Jonathan Kay discusses abstracts POS0070, POS0043 and POS0022 presented at the Eular 2024 meeting in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsADr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
Digital RheumatologyDr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
Drug-resistant RA Does Blinatumomab BiTE?Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.
 

Axial & Psoriatic DiseaseDr. Peter Nash at Eular 2024 in Vienna, Austria.
Difficult to Treat Psoriatic ArthritisDr. Peter Nash reports at Eular 2024 in Vienna, Austria.
Predictors of Treatment Response in Psoriatic ArthritisDr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed: POS 0990POS 0992POS 0266
Prevention of Psoriatic ArthritisDr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsADr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
Digital RheumatologyDr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
Drug-resistant RA Does Blinatumomab BiTE?Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.
Early Diagnosis of Axial SpondyloarthritisDr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria.
Imaging in Axial SpondyloarthritisDr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.